{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for diphenhydramine in Any Name (approximate match)
Status:
US Approved OTC
Source:
21 CFR 341.14(a)(5) cough/cold:antitussive diphenhydramine citrate
Source URL:
First approved in 1946
Source:
BENADRYL by MCNEIL CONS
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Diphenhydramine is an antihistamine which is used in the combination with naproxen sodium for the relief of occasional sleeplessness when associated with minor aches and pains. Diphenhydramine has a role nighttime sleep-aid and naproxen sodium is a pain reliever. In addition, diphenhydramine used in relieving symptoms in patients with moderate-to-severe seasonal allergic rhinitis. Diphenhydramine acts as an antagonist of histamine H1 receptor. Besides, was shown potential to repurpose diphenhydramine as an anti-melanoma therapeutic agent, it induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling pathway.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Amoxydramine is tertiary dialkylarylcarbinol derivative patented by American chemical company Allied Chemical Corp as an antitussive, sedative, and antihypertensive agent.
Status:
First approved in 1951
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Bromodiphenhydramine also known as bromazine, is an antihistamine and anticholinergic agent, which was used to under brand name ambordyl. Ambordyfor was indicated for the treatment of allergic symptoms, but that usage, was discontinued. It was shown, that bromodiphenhydramine competed with free histamine for binding at HA-receptor sites and lead to a reduction of the negative symptoms brought on by histamine HA-receptor binding.